Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%

Abstract Aims Heart failure is a chronic progressive condition, with considerable burden on patients' quality of life and economic burden for the healthcare systems. Before the approval of empagliflozin, there were no proven effective treatments for patients with heart failure with left ventric...

Full description

Bibliographic Details

Published in:	ESC Heart Failure
Main Authors:	Spyros Kolovos, Leana Bellanca, Harinala Groyer, Giuseppe M.C. Rosano, Alexandra Solé, Jennifer Gaultney, Stephan Linden
Format:	Article
Language:	English
Published:	Wiley 2023-12-01
Subjects:	Heart failure with left ventricular ejection fraction (HF LVEF) > 40% Heart failure with preserved ejection fraction Cost‐effectiveness Economic evaluation Empagliflozin SGLT2i
Online Access:	https://doi.org/10.1002/ehf2.14470